JP7113825B2 - 過剰のポリアルコキシル化試薬の回収及び再使用を可能にする核酸のポリアルコキシル化法 - Google Patents

過剰のポリアルコキシル化試薬の回収及び再使用を可能にする核酸のポリアルコキシル化法 Download PDF

Info

Publication number
JP7113825B2
JP7113825B2 JP2019528500A JP2019528500A JP7113825B2 JP 7113825 B2 JP7113825 B2 JP 7113825B2 JP 2019528500 A JP2019528500 A JP 2019528500A JP 2019528500 A JP2019528500 A JP 2019528500A JP 7113825 B2 JP7113825 B2 JP 7113825B2
Authority
JP
Japan
Prior art keywords
nucleic acid
amino
reactant
modified
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500519A5 (enExample
JP2020500519A (ja
Inventor
ベートゲ，ルーカス
Original Assignee
ノクソン・ファルマ・アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノクソン・ファルマ・アクチエンゲゼルシャフト filed Critical ノクソン・ファルマ・アクチエンゲゼルシャフト
Publication of JP2020500519A publication Critical patent/JP2020500519A/ja
Publication of JP2020500519A5 publication Critical patent/JP2020500519A5/ja
Application granted granted Critical
Publication of JP7113825B2 publication Critical patent/JP7113825B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019528500A 2016-11-30 2017-11-30 過剰のポリアルコキシル化試薬の回収及び再使用を可能にする核酸のポリアルコキシル化法 Active JP7113825B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16201391.6 2016-11-30
EP16201391 2016-11-30
PCT/EP2017/001399 WO2018099600A1 (en) 2016-11-30 2017-11-30 A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent

Publications (3)

Publication Number Publication Date
JP2020500519A JP2020500519A (ja) 2020-01-16
JP2020500519A5 JP2020500519A5 (enExample) 2021-01-14
JP7113825B2 true JP7113825B2 (ja) 2022-08-05

Family

ID=57544196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528500A Active JP7113825B2 (ja) 2016-11-30 2017-11-30 過剰のポリアルコキシル化試薬の回収及び再使用を可能にする核酸のポリアルコキシル化法

Country Status (14)

Country Link
US (1) US11459352B2 (enExample)
EP (1) EP3548089B1 (enExample)
JP (1) JP7113825B2 (enExample)
KR (1) KR102611562B1 (enExample)
CN (1) CN110121363B (enExample)
AU (1) AU2017369207C1 (enExample)
BR (1) BR112019009373A8 (enExample)
CA (1) CA3043478C (enExample)
DE (1) DE17829597T1 (enExample)
ES (1) ES2975373T3 (enExample)
MX (1) MX2019006363A (enExample)
RU (1) RU2765027C2 (enExample)
SG (1) SG10202105648XA (enExample)
WO (1) WO2018099600A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046092A (ja) 2002-08-19 2010-03-04 President & Fellows Of Harvard College 進化する新しい分子機能
JP2014514329A (ja) 2011-04-26 2014-06-19 リガド・バイオサイエンシーズ・インコーポレーテツド Ｐｅｇ化オリゴヌクレオチドの製造方法
WO2015113776A1 (en) 2014-02-03 2015-08-06 Noxxon Pharma Ag Methods for the preparation of a polyalkoxylated nucleic acid molecule

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4698579B2 (ja) * 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
WO2005042563A2 (en) * 2003-10-22 2005-05-12 Akzo Nobel N.V. Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
CA2607185A1 (en) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Intracellular active agents
US9388457B2 (en) * 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
DE102007058713A1 (de) * 2007-12-06 2009-06-10 Evonik Goldschmidt Gmbh Silicon(meth-)acrylat-Partikel, Verfahren zu deren Herstellung sowie deren Verwendung
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
JP2014533098A (ja) 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
SG11201405552VA (en) * 2012-03-16 2014-10-30 Merck Patent Gmbh Targeting aminoacid lipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010046092A (ja) 2002-08-19 2010-03-04 President & Fellows Of Harvard College 進化する新しい分子機能
JP2014514329A (ja) 2011-04-26 2014-06-19 リガド・バイオサイエンシーズ・インコーポレーテツド Ｐｅｇ化オリゴヌクレオチドの製造方法
WO2015113776A1 (en) 2014-02-03 2015-08-06 Noxxon Pharma Ag Methods for the preparation of a polyalkoxylated nucleic acid molecule

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RNA Aptamers and Spiegelmers: Synthesis, Purification, and Post-Synthetic PEG Conjugation，Current Protocols in Nucleic Acid Chemistry，2011年，Chapter 4, Unit 4.46.1-30

Also Published As

Publication number Publication date
CN110121363B (zh) 2023-08-29
BR112019009373A8 (pt) 2023-04-11
KR102611562B1 (ko) 2023-12-07
MX2019006363A (es) 2019-11-12
WO2018099600A1 (en) 2018-06-07
SG10202105648XA (en) 2021-06-29
AU2017369207A1 (en) 2019-05-23
AU2017369207C1 (en) 2024-06-27
CN110121363A (zh) 2019-08-13
EP3548089A1 (en) 2019-10-09
AU2017369207A9 (en) 2019-07-25
US20200291057A1 (en) 2020-09-17
RU2019120021A3 (enExample) 2021-04-06
CA3043478C (en) 2023-07-25
CA3043478A1 (en) 2018-06-07
US11459352B2 (en) 2022-10-04
WO2018099600A9 (en) 2023-12-28
WO2018099600A8 (en) 2019-07-04
DE17829597T1 (de) 2019-12-05
RU2019120021A (ru) 2021-01-11
KR20190088062A (ko) 2019-07-25
AU2017369207B2 (en) 2023-12-14
EP3548089C0 (en) 2023-12-27
RU2765027C2 (ru) 2022-01-24
EP3548089B1 (en) 2023-12-27
BR112019009373A2 (enExample) 2019-07-23
JP2020500519A (ja) 2020-01-16
ES2975373T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
EP3355932B1 (en) Oligonucleotide conjugation process
CN106279300B (zh) Rig-i配体及其生产方法
JP7183167B2 (ja) 減少した腎クリアランスを有する多量体オリゴヌクレオチド
JP2018531245A6 (ja) オリゴヌクレオチドコンジュゲーション方法
WO2013176845A1 (en) Retro diels alder reaction as a cleavable linker in dna/rna applications
TWI853845B (zh) 純化寡核苷酸的方法
RU2564855C2 (ru) Способ получения пэгилированных олигонуклеотидов
JP7113825B2 (ja) 過剰のポリアルコキシル化試薬の回収及び再使用を可能にする核酸のポリアルコキシル化法
JP2021072823A (ja) ポリアルコキシル化核酸分子の調製のための方法
JP2023504186A (ja) 標的化された核酸送達のためのペプチドドッキング賦形剤
HK40007263B (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
HK40007263A (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
WO2010017329A1 (en) Molecular entities for binding, stabilization and cellular delivery of charged molecules
HK1255466B (en) Oligonucleotide conjugation process

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220726

R150 Certificate of patent or registration of utility model

Ref document number: 7113825

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350